百乐眠胶囊联合黛力新治疗焦虑性失眠40例

目的?观察百乐眠胶囊联合黛力新治疗焦虑性失眠的临床疗效。方法?筛选焦虑性失眠患者80例，随机分为治疗组与对照组各40例，治疗组给予百乐眠胶囊联合黛力新口服，对照组给予黛力新口服，治疗期间均不服用其他抗焦虑、抗精神病、镇静催眠药物，疗程4周。最终剔除脱落的患者，疗效采用汉密尔顿焦虑量表(HAMA)、睡眠障碍评定量表(SDRS)及PSG参数评定。结果?治疗组SDRS和HAMA在治疗前后的减分差均显著大于对照组（P＜0.05）；治疗后PSG参数（睡眠时间、睡眠潜伏期、睡眠效率），2组均有提高（P<0.05），治疗组优于对照组（P<0.05）;治疗组有效率为84.85%；对照组为61.29%，2组差别具有统计学意义(P＜0.05)。结论?百乐眠胶囊与黛力新联合治疗焦虑性失眠疗效显著，且疗效优于单用黛力新，不增加药物副作用，值得临床推广应用。 

Clinical Effects of Bailemian Capsule Combined with Deanxit in Treating 40 Cases of Insomnia Due to Anxiety

OBJECTIVE?To observe the clinical effects of Bailemian Capsule combined with deanxit in treating patients with insomnia due to anxiety. METHODS?80 patients with insomnia due to anxiety were included and randomly divided into treatment group and control group， with 40 cases in each group. Patients in the treatment group were given Bailemian Capsule combined with deanxit， while whose in the control group were treated with deanxit only， with the treatment course lasting for 4 weeks. No other antianxiety agents， antipsychotics or sedative hypnotics were applied during the study. Patients who dropped out were eliminated from the analysis. Hamilton anxiety scale(HAMA)， sleep dysfunction rating scale(SDRS) and PSG parameters were applied to evaluate the curative effects. RESULTS?Reducing scores on SDRS and HAMA of the treatment group before and after treatment were evidently higher than those of the control group(P<0.05). Both groups were effective in improving PSG parameters including sleeping time， sleep latency and sleep efficiency after treatment(P<0.05)， but the treatment group was superior to the control group(P<0.05). The total curative rate of treatment group and control group were 84.85% and 61.29% respectively， with a statistical significance between the two groups(P<0.05). CONCULSION?Bailemian Capsule combined with deanxit is able to notably improve insomnia due to anxiety without increasing the side effects， which is batter than deanxit intake only， deserving further clinical application and promotion.